

Product Portfolio

inke

Advancing Sustainable
Solutions for Global Health

Portfolio.....	1-2
Pipeline.....	3
Inhalation APIs & Corticosteroids.....	4
CNS APIs.....	5
Ophthalmic HPAPIs.....	6

Therapeutic Area	Product	Indication	API Micronized	Regulatory Documentation
Antiallergics	Loratadine ^P	Allergy	✓	JP DMF
Anti-amyloid	Tafamidis meglumine	Transthyretin amyloidosis	✓	US DMF
Antiasthmatics, COPD and respiratory diseases	Acidinium bromide	COPD	✓	EU-US DMF
	Arformoterol tartrate ^P polymorph A and D	COPD	✓	US-CN-KR DMF
	Ensifentrine ^P	COPD	✓	US DMF
	Formoterol fumarate	Asthma and COPD	✓	CEP / US-CN-JP-KR DMF
	Glycopyrronium bromide ^P	COPD	✓	CEP / US-CN-KR DMF
	Indacaterol maleate ^P	COPD	✓	EU-US-CN-KR DMF
	Montelukast sodium	Asthma, allergic & seasonal rhinitis		EU-JP DMF
	Olodaterol HCl ^P	COPD		EU-US-CN DMF
	Revefenacin	COPD		EU-US-CN DMF
	Salmeterol xinafoate ^P	Asthma and COPD	✓	CEP / US-CN-KR DMF
	Tiotropium bromide	COPD	✓	CEP / US-CN DMF
	Umeclidinium bromide	COPD	✓	EU-US-CN DMF
Antiemetics	Vilanterol trifenate ^P	Asthma and COPD	✓	EU-US DMF
	Aprepitant	Emesis	✓	CEP / US DMF
	Granisetron base ^P	Emesis		US DMF
	Granisetron HCl ^P	Emesis		CEP / US-JP-KR DMF
	Ondansetron base ^P	Emesis	✓	EU-US DMF
Antiglaucoma	Ondansetron HCl ^P	Emesis	✓	CEP / US DMF
	Bimatoprost	Glaucoma / Ocular Hypertension		EU DMF
	Latanoprost	Glaucoma / Ocular Hypertension		CEP / EU-US-CN DMF
	Tafluprost	Glaucoma / Ocular Hypertension		EU DMF
	Travoprost	Glaucoma / Ocular Hypertension		EU-US DMF

Product Portfolio

Therapeutic Area	Product	Indication	API Micronized	Regulatory Documentation
Antihypertensive	Carvedilol ^P	Hypertension, angina, heart failure		JP DMF
	Clevidipine butyrate ^P	Hypertension		EU-US-CN DMF
	Enalapril maleate ^P	Hypertension		CEP / KR DMF
	Imidapril	Hypertension		EU DMF
Antimigrainics	Eletriptan hydrobromide ^P	Migraine	✓	JP DMF
	Zolmitriptan ^P	Migraine	✓	EU-US DMF
Antiparkinson	Tetrabenazine	Huntington's disease chorea and Tardive dyskinesia	✓	EU-US DMF
Antipsychotics	Asenapine maleate ^P	Schizophrenia and acute mania	✓	JP DMF
	Olanzapine ^P	Schizophrenia, psychosis		EU-US-KR DMF
	Risperidone ^P	Schizophrenia, psychosis	✓	CEP / US-CN-KR DMF
Antithrombotics	Prasugrel base ^P	Prophylaxis & therapy of thrombosis		EU DMF
	Rivaroxaban	Thrombosis. Stroke		CEP / US DMF
Spasmolytic	Otilonium bromide	Irritable bowel syndrome		EU DMF

CEP = Products with Certificate of Suitability

P = Patent applications/granted patents owned by Inke

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.



Pipeline

Therapeutic Area	Product	Indication	Samples	Technical Package	Validation Batch	DMF
Antiasthmatics, COPD and respiratory diseases	Budesonide	COPD, Asthma	✓	Pending	Pending	Pending
	Fluticasone furoate	COPD, Asthma	✓	Pending	Pending	Pending
	Fluticasone propionate	COPD, Asthma	Pending	Pending	Pending	Pending
	Indacaterol acetate ^P	Asthma	✓	✓	✓	Q4 2026
	Mometasone furoate anhydrous	Asthma, COPD	Pending	Pending	Pending	Pending
	Mometasone furoate monohydrate	Asthma, COPD	✓	Pending	Pending	Pending
	Roflumilast	COPD	✓	Pending	Q4 2026	Pending
Antiglaucoma	Bimatoprost grenod	Glaucoma / Ocular Hypertension	✓	Pending	Pending	Pending
	Latanoprostene bunod	Glaucoma / Ocular Hypertension	✓	Q1 2027	Q2 2027	Q3 2027
Antiparkinson	Rotigotine ^P	Parkinson's disease	✓	Q3 2026	Q3 2026	Q4 2026
Other disorders	Daprodustat	Anemia due to CKD	Q3 2026	Q4 2026	Q4 2026	Q3 2027
	Daridorexant	Insomnia	✓	Q4 2026	Q3 2026	Q2 2027
	Mavacamten	Cardiomyopathy	✓	Q2 2027	Q1 2027	Q3 2027
	Prasugrel HCl	Prophylaxis & therapy of thrombosis	✓	Pending	Pending	Pending
	Solriamfetol HCl ^P	Narcolepsy	✓	Pending	Pending	Pending
	Tafamidis ^P	Transthyretin amyloidosis	✓	Pending	Pending	Pending

CEP = Products with Certificate of Suitability

P = Patent applications/granted patents owned by Inke

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.



Inhalation APIs

Therapeutic Area	Product	Indication	API Micronized	Regulatory Documentation
Antiasthmatics, COPD and respiratory diseases	Acidinium bromide	COPD	✓	EU-US DMF
	Arformoterol tartrate ^P polymorph A and D	COPD	✓	US-CN-KR DMF
	Ensifentrine ^P	COPD	✓	US DMF
	Formoterol fumarate	Asthma and COPD	✓	CEP / US-CN-JP-KR DMF
	Glycopyrronium bromide ^P	COPD	✓	CEP / US-CN-KR DMF
	Indacaterol maleate ^P	COPD	✓	EU-US-CN-KR DMF
	Montelukast sodium	Asthma, allergic & seasonal rhinitis		EU-JP DMF
	Olodaterol HCl ^P	COPD		EU-US-CN DMF
	Revefenacin	COPD		EU-US-CN DMF
	Salmeterol xinafoate ^P	Asthma and COPD	✓	CEP / US-CN-KR DMF
	Tiotropium bromide	COPD	✓	CEP / US-CN DMF
	Umeclidinium bromide	COPD	✓	EU-US-CN DMF
	Vilanterol trifenate ^P	Asthma and COPD	✓	EU-US DMF

Pipeline

Therapeutic Area	Product	Indication	Samples	Technical Package	Validation Batch	DMF
Antiasthmatics, COPD and respiratory diseases	Budesonide	COPD, Asthma	✓	Pending	Pending	Pending
	Fluticasone Furoate	COPD, Asthma	✓	Pending	Pending	Pending
	Fluticasone Propionate	COPD, Asthma	Pending	Pending	Pending	Pending
	Indacaterol acetate ^P	Asthma	✓	✓	✓	Q4 2026
	Mometasone Furoate Anhydrous	Asthma, COPD	Pending	Pending	Pending	Pending
	Mometasone Furoate Monohydrate	Asthma, COPD	✓	Pending	Pending	Pending
	Roflumilast	COPD	✓	Pending	Q4 2026	Pending

CEP = Products with Certificate of Suitability

P = Patent applications/granted patents owned by Inke

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.



Therapeutic Area	Product	Indication	API Micronized	Regulatory Documentation
Antimigrainics	Eletriptan hydrobromide ^P	Migraine	✓	JP DMF
	Zolmitriptan ^P	Migraine	✓	EU-US DMF
Antiparkinson	Tetrabenazine	Huntington's disease chorea and Tardive dyskinesia	✓	EU-US DMF
Antipsychotics	Asenapine maleate ^P	Schizophrenia and acute mania	✓	JP DMF
	Olanzapine ^P	Schizophrenia, psychosis		EU-US-KR DMF
	Risperidone ^P	Schizophrenia, psychosis	✓	CEP / US-CN-KR DMF

Pipeline

Therapeutic Area	Product	Indication	Samples	Technical Package	Validation Batch	DMF
Antiparkinson	Rotigotine ^P	Parkinson's disease	✓	Q3 2026	Q3 2026	Q4 2026
Other disorders	Daridorexant	Insomnia	✓	Q2 2026	Q3 2026	Q4 2026
	Solriamfetol HCl ^P	Narcolepsy	✓	Pending	Pending	Pending

CEP = Products with Certificate of Suitability
P = Patent applications/granted patents owned by Inke

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.



Ophthalmic APIs

Therapeutic Area	Product	Indication	API Micronized	Regulatory Documentation
Antiglaucoma	Bimatoprost	Glaucoma / Ocular Hypertension		EU DMF
	Latanoprost	Glaucoma / Ocular Hypertension		CEP / EU-US-CN DMF
	Tafluprost	Glaucoma / Ocular Hypertension		EU DMF
	Travoprost	Glaucoma / Ocular Hypertension		EU-US DMF

Pipeline

Therapeutic Area	Product	Indication	Samples	Technical Package	Validation Batch	DMF
Antiglaucoma	Bimatoprost grenod	Glaucoma / Ocular Hypertension	✓	Pending	Pending	Pending
	Latanoprostene bunod	Glaucoma / Ocular Hypertension	✓	Q1 2027	Q2 2027	Q3 2027

CEP = Products with Certificate of Suitability
P = Patent applications/granted patents owned by Inke

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

